Nutramin Injection

Adult dosage

Intravenous drip of a maximum of 1.5 g of total amino acids per day per kg of body weight (2100 mL per day for a body weight of 70 kg). The administration rate is 1.7–2.1 mL per kg of body weight over 60 minutes (40–50 drops per minute for a body weight of 70 kg).

This medication must be used strictly according to a doctor's instructions. It should not be used in patients with severe renal impairment or hypernitrogenemia. Patients with amino acid metabolism abnormalities other than liver dysfunction should also avoid this medication. It should not be administered to patients with metabolic disorders that interfere with nitrogen utilization. Persons with cachectic heart failure or pulmonary edema should not use this medication. Patients with almost no urine output or anuria are also not suitable for administration. This medication contains sodium and chloride ions, and caution is warranted in patients with hypernatremia, hyperchloremia, or alkalosis. If magnesium ions are included, it should not be administered to patients with heart block or severe myasthenia gravis. Patients with excessive fluid supply or a history of myocardial infarction should also avoid using this medication. In patients with severe acidosis, congestive or severe heart failure, it should be administered cautiously. If sodium ions are present, care is needed for patients with edema due to sodium retention. If potassium ions are present, caution is required for patients with hyperkalemia or potassium retention. Administration should also be cautious in patients with reduced kidney function. This medication may rarely cause hypersensitivity reactions such as skin rashes, and in such cases, use should be immediately discontinued. Gastrointestinal symptoms such as nausea or vomiting may occasionally occur. Cardiovascular abnormalities such as chest discomfort, palpitations, rapid pulse, and increased blood pressure may also occur. Rapid administration of large amounts can lead to acidosis, so caution is necessary. Severe side effects such as chills, fever, headache, respiratory distress, shock, bronchospasm, and ureteral spasm have also been reported. If magnesium ions are included, peripheral vasodilation symptoms may occur. Various metabolic complications including metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, etc. may develop. In patients with poor liver or kidney function, blood urea nitrogen levels may increase. Patients with severely reduced liver function may be at risk for serum amino acid imbalance or coma. When administering large amounts of this medication or using it with electrolyte solutions, careful management of electrolyte balance is necessary. Care should be taken as metabolic alkalosis may occur in cases of overdose. Patients with a history of kidney disease, lung disease, or heart disease should be administered cautiously while avoiding fluid overload. Diabetic patients should frequently check their blood glucose levels. Patients with hyponatremia, liver, or renal dysfunction should be particularly diligent about dose adjustments and monitoring fluid and electrolyte levels. The use of tetracycline antibiotics concurrently may reduce protein-sparing effects. If magnesium ions are included, caution should be taken when administering with calcium salts to avoid precipitation. The safety has not been established in pregnant women, and it should only be administered when the therapeutic benefit outweighs the risk. In children, since liver function may be immature, it is advisable to maintain a lower concentration for administration. In particular, infants may develop hyperammonemia due to a deficiency in urea synthesis capacity, so blood ammonia levels should be frequently monitored. In the elderly, physical functions may be decreased, so the administration speed should be slow, and the dose should be reduced. This medication contains electrolytes, so care should be taken to maintain electrolyte balance during large volume infusions, and intravenous administration should be performed slowly. Rapid infusions can cause chills or vomiting and lead to amino acid loss. In cold weather, it is advisable to warm the medication to body temperature before use. To reduce the risk of infection during administration, preparation should be done in a sterile environment, and care should be taken to ensure the sterility of injection equipment. If the solution is cloudy or discolored, it should not be used, and it should be used quickly after preparation and not exceed 24 hours if refrigerated. If precipitates form, it should be warmed at 50-60 degrees and then cooled to body temperature for use. During storage, do not open the packaging, and if there is any abnormality in the solution or damage to the packaging, it should not be used. Soft bag products do not require venting, while vial products need to be vented at the time of administration.

Serious side effects

• Respiratory distress
• respiratory arrest
• shock
• bronchospasm.

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid pulse
• increased blood pressure
• metabolic acidosis
• hypophosphatemia
• alkalosis

This medication should be stored in a sealed container to prevent air entry and ideally kept at a temperature between 1 to 30 degrees Celsius. This storage method helps maintain the effectiveness of the medication.

Appearance

A colorless to light yellow transparent injection contained in a plastic container for infusion.

Package unit

Bag - 250 milliliters / Bag